Tulisokibart

Phase 2Small molecule

Merck & Co.

Tulisokibart is one of 200 small molecule programs targeting Arthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

199

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArthritisActive, not recruiting

Interstitial Lung DiseaseActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Ulcerative ColitisActive, not recruiting

Psoriatic ArthritisActive, not recruiting

Hidradenitis SuppurativaActive, not recruiting

Radiographic Axial SpondyloarthritisRecruiting

ArthritisPhase 2

Active, not recruiting

Interstitial Lung DiseasePhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Ulcerative ColitisPhase 2

Active, not recruiting

Psoriatic ArthritisPhase 2

Active, not recruiting

Hidradenitis SuppurativaPhase 2

Active, not recruiting

Radiographic Axial SpondyloarthritisPhase 2

Recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Actemra

Cimzia

30 3

Simponi

Johnson & Johnson

Preclinical

19 4

Tulisokibart

Merck & Co.

Phase 2

1 5

Enbrel

IImmunex

Preclinical

64 6

Arcoxia

Novartis

Preclinical

4 7

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 8

Ilaris

Novartis

Preclinical

3 9

Actos

Takeda

Preclinical

2 10

Celexa

AbbVie

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

ART

NCT07405177

Q1 2029

Phase 2Active, not recruiting

Hidradenitis Suppurativa

NCT06956235

Q3 2029

Phase 2Active, not recruiting

Interstitial Lung Disease

NCT05270668

Phase 2Recruiting

Rheumatoid Arthritis

NCT07176390

Q1 2030

Phase 2Recruiting

Psoriatic Arthritis

NCT07486960

Phase 2Recruiting

Radiographic Axial Spondyloarthritis

NCT07133633

Clinical

Trials by Indication[1]

Ulcerative Colitis2 trials

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06651281·1,380 enrolled

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04996797·178 enrolled

ART2 trials

Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06575595·60 enrolled

A Study of MK-7240 in Healthy Participants (MK-7240-009)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT07405177·330 enrolled

Hidradenitis Suppurativa1 trial

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06956235·147 enrolled

Single Dose1 trial

Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06829225·48 enrolled

Interstitial Lung Disease1 trial

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT05270668·154 enrolled

3 more indications

Rheumatoid Arthritis1 trial

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07176390·182 enrolled

Radiographic Axial Spondyloarthritis1 trial

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07133633·315 enrolled

Psoriatic Arthritis1 trial

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07486960·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Tulisokibart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tulisokibart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tulisokibart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

Tulisokibart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2029

Q3 2029

Q1 2030

Trials by Indication[1]

Ulcerative Colitis2 trials

ART2 trials

Hidradenitis Suppurativa1 trial

Single Dose1 trial

Interstitial Lung Disease1 trial

Rheumatoid Arthritis1 trial

Radiographic Axial Spondyloarthritis1 trial

Psoriatic Arthritis1 trial

References

Drug Info

Quick Facts

Related News